ERBB2 and neoplasm: Experimental verification shows that iMSCEndostatin exhibits extraordinary recognition/distinguishing ability for normal tissue cells from Her2 (+) tumor cells, which can precise deployment of endostatin at the tumor site, and locking treatment and drug toxicity to the lesion.